Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Auschwitz Committee wants German auction of Holocaust items scrapped - 2How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- 3The most effective method to Connect Successfully with Teachers in a Web based Setting
- 4Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- 5Grasping the Basics of Business Land Regulation
- How to watch the last supermoon of the year
- I'm a hypnotherapist who helps day traders who are losing money. Here's why I think hypnosis works.
- Are protests pushing Iran's Islamic regime toward a tipping point?
- Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Tear gas and arrests: Iranian regime continues crackdown on protesters amid economic unrest
- Figure out How to Adjust Work, Life, and an Internet based Degree
- 6 Vehicle Rental Administrations: Pick Your Ideal Ride
- I took my shoes off and went for a barefoot hike. I couldn’t believe what happened next
- Manual for Notorious Fragrances: Immortal Aromas
